The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).
Betty Y Chang
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Richard R. Furman
Consultant or Advisory Role - Pharmacyclics
Marc Zapatka
No relevant relationships to disclose
Jacqueline Claudia Barrientos
Research Funding - Pharmacyclics
Daniel Li
Consultant or Advisory Role - Pharmacyclics
Susanne Steggerda
Consultant or Advisory Role - Pharmacyclics
Karl Eckert
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Michelle Francesco
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Jennifer Ann Woyach
No relevant relationships to disclose
Amy J Johnson
No relevant relationships to disclose
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Matthias Versele
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
John C. Byrd
Consultant or Advisory Role - Pharmacyclics (U)
Research Funding - Pharmacyclics
Stephan Stilgenbauer
Consultant or Advisory Role - Pharmacyclics
Honoraria - Pharmacyclics
Research Funding - Pharmacyclics
Joseph J. Buggy
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics